Halfon 2003.

Methods	N=11 Non Randomized Fup: not reported, w/o d/o: reported
Participants	Eligibility: ‐ HAART failure Baseline primary mutations: minimum two Baseline mean CD4 314 (22‐1510) Baseline mean HIV RNA 4.45 (2.9‐5.7)
Interventions	3 month TI
Outcomes	CD4 decline: present in all participants VL rebound: VL<70,000 cop/ml in 8/11 participants; VL >300,000 cop/ml in 3/11 participants Viral Reversion: 2 participants Mutations: 2 participants
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	D ‐ Not used